Genentech 2Q Revenues: $2.2 billion (+44%) 2Q Earnings: $531 million (+79%) YTD Revenues: $4.2 billion (+40%) YTD Earnings: $952 million (+64%) Comments: U.S. product sales increased 41% in the quarter to $1.7 billion driven by Rituxan sales, up 17% to $526 million; Avastin sales up 72% to $423 million; Herceptin sales up 111% to $320 million and Tarceva sales up 47% to $103 million. R&D expenses increased 40% to $390 million in the quarter....